Form 4: Innoviva Director Acquires Shares and Options

Innoviva, Inc. director Jules Haimovitz acquired 9,786 shares of common stock and 10,000 non-statutory stock options.

Summary

• Jules Haimovitz, a Director at Innoviva, Inc., reported a transaction on May 4, 2026.
• The transaction involved the acquisition of 9,786 shares of common stock.
• Additionally, Haimovitz acquired 10,000 non-statutory stock options with an exercise price of $22.99.
• These acquisitions were part of an equity grant received upon the conclusion of the Issuer's 2026 annual meeting of stockholders.
• Both the restricted stock units (RSUs) and stock options are subject to vesting conditions, including continuous service as an Outside Director.
• Vesting is scheduled for the sooner of the next annual stockholder meeting or the one-year anniversary of the grant date.
• Accelerated vesting is possible upon the director's death, disability, or a change in control event, provided continuous service until such event.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard equity grant to a director rather than a significant financial event or change in company performance.

Positives

• Director Haimovitz's acquisition of stock and options indicates continued commitment and alignment with the company's performance.
• The grant of equity awards is a common incentive to retain and motivate key personnel, particularly directors.

Risks

• Vesting of the acquired securities is contingent upon continuous service as an Outside Director, meaning a departure before the vesting date could result in forfeiture.
• The value of the stock options is subject to market fluctuations and the company's future stock performance.

Future Outlook

The future outlook for the acquired equity is tied to the company's performance and the director's continued service, with vesting contingent on meeting specific service and event-based criteria.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology and pharmaceutical sectors, like Innoviva, Inc., to align director incentives with shareholder value and ensure long-term commitment.

Stakeholder Impact

• Shareholders: The transaction aligns director incentives with shareholder interests, potentially leading to better long-term company performance.
• Employees: Standard equity grants to directors do not typically have a direct impact on employees, but successful company performance driven by aligned leadership benefits all stakeholders.
• Management: Reinforces the compensation structure for directors.

Next Steps

• Director Haimovitz will continue to serve as an Outside Director.
• The acquired RSUs and Options will vest according to the schedule outlined, subject to continuous service and potential accelerated vesting events.

Key Dates

Keywords

Innoviva Inc, INVA, Form 4, Director, Stock Options, Restricted Stock Units, Equity Grant, Beneficial Ownership, Vesting Schedule